2021
Emerging Role of Immune Therapy in HCC
Stein S. Emerging Role of Immune Therapy in HCC. Digestive Disease Interventions 2021, 05: 277-282. DOI: 10.1055/s-0041-1722932.Peer-Reviewed Original ResearchTyrosine kinase inhibitorsHepatocellular carcinomaImmune therapySingle-agent PD-1 inhibitionVascular endothelial growth factor inhibitionMultiple tyrosine kinase inhibitorAbstract Hepatocellular carcinomaPrevalent cancer diagnosesUnprecedented response ratesPD-1 inhibitionAdvanced hepatocellular carcinomaGrowth factor inhibitionAdvanced diseaseDurable responsesPD-1Combination therapyTreatment optionsFactor inhibitionResponse rateTherapy drugsPatientsKinase inhibitorsTherapyCancer diagnosisModest improvement
2020
PD-1 targeted immunotherapy for advanced hepatocellular cancer: Current utilization and outcomes in the United States.
Uhlig J, Stein S, Kim K. PD-1 targeted immunotherapy for advanced hepatocellular cancer: Current utilization and outcomes in the United States. Journal Of Clinical Oncology 2020, 38: e16647-e16647. DOI: 10.1200/jco.2020.38.15_suppl.e16647.Peer-Reviewed Original ResearchAdvanced hepatocellular carcinomaHepatocellular carcinomaOverall survivalPD-1Multivariable analysisLiver disease risk factorsCox proportional hazards modelBilirubin resultsAdvanced hepatocellular cancerClinical performance statusLiver disease complicationsOverall survival benefitDisease risk factorsDeath protein 1Longer overall survivalOncological treatment strategiesProportional hazards modelDe-identified databaseSystemic sorafenibAdult patientsHCC resectionPatient demographicsPerformance statusSurvival benefitIndependent prognosticator